Generic Sterile Injectable Market Size is Projected to Reach US$ 203.66 Billion by 2030

Canada – The generic sterile injectable market was valued at 77.41 billion USD in 2021 and will grow with a CAGR of 11.3% from 2021 to 2030.

The generic sterile injectable market size is forecasted to reach around US$ 203.66 billion by 2030. The report contains 150+ pages with detailed analysis

Precedence Research is a Canada based company announced report on “Generic Sterile Injectable Market (By Product Type: Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulin, Blood Factors, Antibiotics, and Others; By Therapeutic Application: Cancer, Diabetes, Cardiovascular Disease, Central Nervous System, Musculoskeletal System, and Others; By Distribution Channel: Hospitals, Drug Stores, Retail Pharmacies, and Others) – Global Industry Analysis, Market Size, Share, Growth, Trends, Regional Outlook and Forecasts, 2021 – 2030”.

What is the sterile injectable generic?

The sterile injectable generic refers to the biologics used for the treatment of a variety of medications which includes the same active ingredients found in the marketed versions. Its inactive contents can, however, vary from one another. The generic sterile injectable development process is governed by the U.S. The FDA and its marketed equivalents are similar. U.S. according to National Center for Health Information, it is considered a chronic condition when the disease lasts more than three months within the patient. Chronic diseases are one of the key causes of death, as vaccines and other drugs do not cure them quickly.

Market Estimations Y-O-Y:

  • Market Size Was Valued In 2021: US$ 203.66 Billion
  • Market Size Is Projected to Grow By 2022: US$ 86.11 Billion
  • Market Size Is Projected to Grow By 2023: US$ 95.82 Billion
  • Market Size Is Projected to Grow By 2024: US$ 106.64 Billion
  • Market Size Is Projected to Grow By 2025: US$ 118.72 Billion
  • Market Size Is Projected to Grow By 2026: US$ 132.19 Billion
  • Market Size Is Projected to Grow By 2027: US$ 147.22 Billion
  • Market Size Is Projected to Grow By 2028: US$ 164.00 Billion
  • Market Size Is Projected to Grow By 2029: US$ 182.74 Billion
  • Market Size Is Projected to Grow By 2030: US$ 203.66 Billion
  • Compound Annual Growth Rate (CAGR) from 2022 to 2030: 11.3 percent

Growth Factors:

The demand for sterile injectable in the coming years is expected to drive a growing prevalence of chronic diseases, particularly cancer, across the globe. Moreover, the growth of the global industry is also being fuelled by a rising number of drug manufacturers focused on the development of cancer drugs. In addition, rapid FDA sterile injectable drug approvals coupled with shortened approval times for new drug manufacture in cancer treatment are growing the availability of dive drugs and ultimately powering demand in the generic sterile injectable market. An alternative to the oral delivery mechanism is injectable drug delivery, which easily transports a drug dose through the bloodstream, thereby bypassing first-pass metabolism. There are some medications that would be entirely useless if delivered as capsules, as they would be killed by enzymes that digest food in the stomach.

The insulin injection used in diabetes care is an example. Insulin is a protein. Therefore, if given as a tablet, the same enzymes that ferment food in the stomach would be digested. Therefore, as of today, there is no such term as an insulin tablet. Injectable allow the transport, directly into the bloodstream, of drugs manufactured in liquid form. The goal of the delivery of injectable drugs is to optimize patient compliance and reduce the frequency of dose administration without reducing medication efficacy. Due to deep vomiting, unconsciousness or having a cancer lining in the upper part of their dietary canal, it may be impossible to take tablets for certain patients. Therefore, injection options are available for most oral medications. The increasing prevalence of such metabolic disease aids in the overall growth in the sterile injectable market over the globe.

Scope of the Generic Sterile Injectable Market

Report Highlights Details
Segments Covered Product, Therapeutic Application, Distribution Channel, Region
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)
Base Year 2021
Historic Data 2017 to 2021
Forecast Period 2022 to 2030

Regional Analysis:

The report offers research data for North America, Asia Pacific, Europe, and Middle East and Africa and Latin America. In year 2020, North America conquered the worldwide market with a market share of greater than 25%. United States signified as the highest share holding country in the North America region primarily due to advanced healthcare infrastructure, increasing prevalence of chronic diseases, and presence of leading layers in the countries of the North America. Asia Pacific generic sterile injectable industry market is estimated to grow at noteworthy rate of growth in the next 10 years.

The China generic sterile injectable industry market is anticipated to dominate in terms of revenue in the Asia Pacific region. Increasing the prevalence of chronic diseases among the population along with increasing initiatives by the regulatory bodies to control them in the countries of the region is a main driver growth of the APAC. Nevertheless, emerging markets in the APAC region is creating growth opportunities in the target market. African, Latin America and Middle Eastern region will register perceptible growth during the prediction period particularly in the nations including Mexico, Brazil, and GCC, of the regions.

COVID-19 Impact:

The industrial report mentions the influence of the ongoing COVID-19 pandemic. The outbreak has caused disturbances in several industries and has hammered the logistics, resulting in delayed deliveries and cancellation of product demand. The generic sterile injectable report proficiently explains the resulting factors and concerns of manufacturers. Researchers have also well-explained how the producers and providers will tackle the ongoing epidemic and the key strategies to be adopted post-pandemic for turning their businesses back to normal.

Key Players:

The generic sterile injectable market is consolidated with a major number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report. Primary research represents a bulk of research efforts, supplemented by extensive secondary research.

Some of the prominent players in the generic sterile injectable market include:

  • Fresenius Kabi
  • Baxter
  • Civica
  • Pfizer
  • Mylan
  • Hikma
  • Sandoz
  • Teva
  • Nichi-Iko
  • 3M
  • Merck & Co., Inc.
  • Others

Market Segmentation

By Product Type

  • Monoclonal Antibodies
  • Cytokines
  • Insulin
  • Peptide Hormones
  • Vaccines
  • Immunoglobulin
  • Blood Factors
  • Antibiotics
  • Others

By Therapeutic Application

  • Cancer
  • Diabetes
  • Cardiovascular Disease
  • Central Nervous System
  • Musculoskeletal System
  • Others

By Distribution Channel

  • Hospitals
  • Drug Stores
  • Retail Pharmacies
  • Others

Regional Segmentation

  • North America (U.S. and Canada)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Generic Sterile Injectable Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Generic Sterile Injectable Market

5.1. Covid-19: generic sterile injectable Industry Impact
5.2. generic sterile injectable Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and generic sterile injectable Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for generic sterile Injectable Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Generic Sterile Injectable Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. The convenience of sterile injectable in medical treatment boosts the market
6.1.1.2. Development in biotechnology aids rapid investment in injectable
6.1.1.3. Increasing prevalence of chronic illnesses across the globe
6.1.2. Market Restraints
6.1.2.1. High entry barriers due to demanding compliance requirements
6.1.3. Market Opportunities
6.1.3.1. Expiry of patents

Chapter 7. Global Generic Sterile Injectable Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. generic sterile Injectable Market Revenue by Market Players (2017 – 2020)
7.1.1.2. generic sterile Injectable Market Revenue Market Share by Market Players (2017 – 2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Generic Sterile Injectable Market, By Product Type

8.1. generic sterile Injectable Market, by Product Type, 2017-2030
8.1.1. Monoclonal Antibodies
8.1.1.1. Market Revenue Forecast (2017-2030)
8.1.2. Cytokines
8.1.2.1. Market Revenue Forecast (2017-2030)
8.1.3. Insulin
8.1.3.1. Market Revenue Forecast (2017-2030)
8.1.4. Peptide Hormones
8.1.4.1. Market Revenue Forecast (2017-2030)
8.1.5. Vaccines
8.1.5.1. Market Revenue Forecast (2017-2030
8.1.6. Immunoglobulin
8.1.6.1. Market Revenue Forecast (2017-2030)
8.1.7. Blood Factors
8.1.7.1. Market Revenue Forecast (2017-2030)
8.1.8. Antibiotics
8.1.8.1. Market Revenue Forecast (2017-2030)
8.1.9. Others
8.1.9.1. Market Revenue Forecast (2017-2030)

Chapter 9. Global Generic Sterile Injectable Market, By Therapeutic Application

9.1. generic sterile injectable Market, by Therapeutic Application, 2017-2030
9.1.1. Cancer
9.1.1.1. Market Revenue Forecast (2017-2030)
9.1.2. Diabetes
9.1.2.1. Market Revenue Forecast (2017-2030)
9.1.3. Cardiovascular Disease
9.1.3.1. Market Revenue Forecast (2017-2030)
9.1.4. Central Nervous System
9.1.4.1. Market Revenue Forecast (2017-2030)
9.1.5. Musculoskeletal System
9.1.5.1. Market Revenue Forecast (2017-2030)
9.1.6. Others
9.1.6.1. Market Revenue Forecast (2017-2030)

Chapter 10. Global Generic Sterile Injectable Market, By Distribution Channel

10.1. generic sterile injectable Market, by Distribution Channel, 2017-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue Forecast (2017-2030)
10.1.2. Drug Stores
10.1.2.1. Market Revenue Forecast (2017-2030)
10.1.3. Retail Pharmacies
10.1.3.1. Market Revenue Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue Forecast (2017-2030)

Chapter 11. Global Generic Sterile Injectable Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Product Type(2017-2030)
11.1.2. Market Revenue Forecast by Therapeutic Application (2017-2030)
11.1.3. Market Revenue Forecast by Distribution Channel (2017-2030)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2017-2030)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2017-2030)
11.2. Europe
11.2.1. Market Revenue Forecast by Product Type (2017-2030)
11.2.2. Market Revenue Forecast by Therapeutic Application (2017-2030)
11.2.3. Market Revenue Forecast by Distribution Channel (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2017-2030)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2017-2030)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Product Type (2017-2030)
11.3.2. Market Revenue Forecast by Therapeutic Application (2017-2030)
11.3.3. Market Revenue Forecast by Distribution Channel (2017-2030)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2017-2030)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2017-2030)
11.4. LATAM
11.4.1. Market Revenue Forecast by Product Type (2017-2030)
11.4.2. Market Revenue Forecast by Therapeutic Application (2017-2030)
11.4.3. Market Revenue Forecast by Distribution Channel (2017-2030)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2017-2030)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2017-2030)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Product Type (2017-2030)
11.5.2. Market Revenue Forecast by Therapeutic Application (2017-2030)
11.5.3. Market Revenue Forecast by Distribution Channel (2017-2030)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2017-2030)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2017-2030)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2017-2030)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2017-2030)

Chapter 12. Company Profiles

12.1. Fresenius Kabi
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Application
12.1.3. Revenue, Price, and Gross Margin (2017-2020)
12.1.4. Recent Developments and Strategies
12.2. Baxter
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Application
12.2.3. Revenue, Price, and Gross Margin (2017-2020)
12.2.4. Recent Developments and Strategies
12.3. Civica
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Application
12.3.3. Revenue, Price, and Gross Margin (2017-2020)
12.3.4. Recent Developments and Strategies
12.4. Pfizer
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Application
12.4.3. Revenue, Price, and Gross Margin (2017-2020)
12.4.4. Recent Developments and Strategies
12.5. Mylan
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Application
12.5.3. Revenue, Price, and Gross Margin (2017-2020)
12.5.4. Recent Developments and Strategies
12.6. Hikma
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Application
12.6.3. Revenue, Price, and Gross Margin (2017-2020)
12.6.4. Recent Developments and Strategies
12.7. Sandoz
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Application
12.7.3. Revenue, Price, and Gross Margin (2017-2020)
12.7.4. Recent Developments and Strategies
12.8. Teva
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Application
12.8.3. Revenue, Price, and Gross Margin (2017-2020)
12.8.4. Recent Developments and Strategies
12.9. Nichi-Iko
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Application
12.9.3. Revenue, Price, and Gross Margin (2017-2020)
12.9.4. Recent Developments and Strategies
12.10. 3M
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Application
12.10.3. Revenue, Price, and Gross Margin (2017-2020)
12.10.4. Recent Developments and Strategies
12.11. Merck & Co., Inc.
12.11.1. Company Overview, Business Information, Regional Presence
12.11.2. Product Portfolio Analysis
12.11.2.1. Product Details, Specification, Application
12.11.3. Revenue, Price, and Gross Margin (2017-2020)
12.11.4. Recent Developments and Strategies

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.